XmAb24306

DB17526InvestigationalProtein Based Therapies

XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.

Mechanism: Pharmacologically active on Interleukin-2 receptor subunit beta
Curator reviewed
Code names: RG-6323 · RO-7310729 · XmAb24306 · XmAb 306

Resolves to

Targets

P14784IL2RB

What you can answer from here — as of September 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with XmAb24306, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account